Ted Schroeder's guest appearances

Ted Schroeder

Finding Genius Podcast

FutureTech Podcast

Progressive Cattle Podcast

Laura Potterat

Marc Guell

Paul Turner

Jan Vijg

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

Kim Kush

OwlTail

Dave Nichols

In this episode, Paul visits with Dave Nichols, an emeritus professor at Kansas State University about his experiences as a livestock judge and educator, discussing opportunities to bridge the gap between agriculture and consumers. David also visits with K-State ag economist Ted Schroeder about the changing elements in the cattle markets, and the potential pitfalls of mandating cash cattle markets. David, Paul and Carrie also share a preview of the November issue, and share what they're grateful for this Thanksgiving season.

In this episode, Paul visits with Dave Nichols, an emeritus professor at Kansas State University about his experiences as a livestock judge and educator, discussing opportunities to bridge the gap between agriculture and consumers. David also visits with K-State ag economist Ted Schroeder about the changing elements in the cattle markets, and the potential pitfalls of mandating cash cattle markets. David, Paul and Carrie also share a preview of the November issue, and share what they're grateful for this Thanksgiving season.

Ag youth and cattle market dynamics – with Dave Nichols and Ted Schroeder

For over three decades now, Ted Schroeder has worked in and around the pharmaceutical industry in the sales, marketing, and development of antibiotics. As the CEO of Nabriva Therapeutics, he has unique insights on the current development of two antibiotics which may be effective in treating community-acquired pneumonia in adults and serious urinary tract infections that do not respond to many other types of drugs. On today’s podcast, you will learn:   What community-acquired pneumonia is and why it can be hard to treat What makes gram-negative bacterial infections more challenging to treat than gram-positive bacterial infections How strong the clinical-based evidence is for the effectiveness of these antibiotics What’s to come in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents   Interested in learning more? Press play and visit https://www.nabriva.com/

For over three decades now, Ted Schroeder has worked in and around the pharmaceutical industry in the sales, marketing, and development of antibiotics. As the CEO of Nabriva Therapeutics, he has unique insights on the current development of two antibiotics which may be effective in treating community-acquired pneumonia in adults and serious urinary tract infections that do not respond to many other types of drugs. On today’s podcast, you will learn: <ul> <li>What community-acquired pneumonia is and why it can be hard to treat</li> <li>What makes gram-negative bacterial infections more challenging to treat than gram-positive bacterial infections</li> <li>How strong the clinical-based evidence is for the effectiveness of these antibiotics</li> <li>What’s to come in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents</li> </ul> Interested in learning more? Press play and visit <a href="https://www.nabriva.com/" rel="nofollow" target="_blank">https://www.nabriva.com/</a>

On New and Emerging Antibiotics in the U.S.—Ted Schroeder—Nabriva Therapeutics

For over 30 years, Ted Schroeder has been involved in the sales, marketing, and development of antibiotics, and he currently serves as the CEO of Nabriva Therapeutics. He joins the podcast today to discuss the current work being done at Nabriva, which involves the development of a new class of IV antibiotics for the treatment of community-acquired pneumonia in adults—the first of its kind in the US in over two decades.  The second product Nabriva is working on has been around for nearly four decades but has never been available in the US, and it’s been shown to be effective in tackling complicated urinary tract infections and multidrug-resistant strains of bacteria. These antibiotics could limit or altogether eliminate the need for hospital stays for many people. To learn more about the work being done, tune in. You’ll discover the details of all this and more, including:   What makes gram negative bacterial infections so much more difficult to treat than gram-positive bacterial infections How strong the clinical-based evidence is for the effectiveness of these antibiotics What’s on the horizon in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents   For more information, visit https://www.nabriva.com/.

For over 30 years, Ted Schroeder has been involved in the sales, marketing, and development of antibiotics, and he currently serves as the CEO of Nabriva Therapeutics. He joins the podcast today to discuss the current work being done at Nabriva, which involves the development of a new class of IV antibiotics for the treatment of community-acquired pneumonia in adults—the first of its kind in the US in over two decades.  The second product Nabriva is working on has been around for nearly four decades but has never been available in the US, and it’s been shown to be effective in tackling complicated urinary tract infections and multidrug-resistant strains of bacteria. These antibiotics could limit or altogether eliminate the need for hospital stays for many people. To learn more about the work being done, tune in. You’ll discover the details of all this and more, including: <ul> <li>What makes gram negative bacterial infections so much more difficult to treat than gram-positive bacterial infections</li> <li>How strong the clinical-based evidence is for the effectiveness of these antibiotics</li> <li>What’s on the horizon in the near future for Nabriva Therapeutics, pharmacology, and anti-infective agents</li> </ul> For more information, visit <a href="https://www.nabriva.com/" rel="nofollow" target="_blank">https://www.nabriva.com/</a>.

On the Development of Novel Antibiotics -Ted Schroeder - Nabriva Therapeutics